Trial Profile
Nivolumab and Oral Cyclophosphamide for Relapsed/Refractory Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndrome (MDS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 May 2023
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Nivolumab (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 11 Apr 2022 Status changed from suspended to completed.
- 12 Mar 2021 Planned primary completion date changed from 1 Feb 2021 to 1 Feb 2023.
- 18 Dec 2019 Status changed from recruiting to suspended.